TrialJournal of the American Heart Association2022

Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.

Gary E Raskob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.